ScanCell's melanoma vaccine triggers immune responses; Taiwan Liposome heading toward IPO;


> Scancell's DNA ImmunoBody vaccine, in a Phase I/II trial for malignant melanoma, has triggered an immune response in four of 6 patients treated. The vaccine is delivered using Ichor Medical Systems' TriGrid electroporation delivery device. Press release

Transplant rejection

> The FDA has accepted Astellas Pharma's NDA for its tacrolimus extended-release capsules for the prevention of liver and kidney transplant rejection. Press release

Pain and CNS disorders

> Millennium Laboratories has launched a test to monitor the levels of drug in patients using Butrans, a transdermal buprenorphine patch. This is designed to work with the low levels of drug associated with transdermal delivery. Press release

> The FDA has voted against approval of Zogenix's Zohydro ER extended-release hydrocodone capsules for the management of moderate-to-severe chronic pain. Press release

> Phase III trials of Osmotica Pharmaceutical's extended-release arbaclofen tablets have begun recruitment. The study will look at safety and efficacy in patients with spasticity due to multiple sclerosis. Press release

Drug delivery

> 3-D printers could print out needle arrays for drug delivery … but not quite yet. Article

> Using thin films could help proteins to slip through the skin. Article

Financial and patent news

> Australian company OBJ is on the way to getting a European patent to protect its electromagnetic drug delivery technology, Dermaportation. Article

> Taiwan Liposome expects to raise $20.3 million from an IPO, with plans to spend the cash on improving its gross margin and strengthening its bottom line. Article

> Aegis Therapeutics has been awarded a U.S. patent for absorption-enhancing self-assembling aqueous hydrogels that could be used in extended-release, transdermal or transmucosal drug delivery. Press release

And Finally… CFD Research has been given a $1.3 million grant to develop an in vitro tumor model. SynVivo-Tumor replicates the tumor microenvironment and could help to develop drug delivery systems. Press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.